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 1	  
Abstract  2	  
Novel approaches for adjunctive therapy are urgently needed for infections complicated 3	  
by antibiotic-resistant pathogens and for patients with compromised immunity. 4	  
Necrotizing fasciitis (NF) is a destructive skin and soft tissue infection. Despite treatment 5	  
with systemic antibiotics and radical debridement of necrotic tissue, lethality remains 6	  
high. The key iron regulatory hormone hepcidin was originally identified as a cationic 7	  
antimicrobial peptide (AMP), but its putative expression and role in the skin, a major 8	  
site of AMP production, has never been investigated. We report here that hepcidin 9	  
production is induced in the skin of patients with Group A Streptococcal (GAS) NF. In a 10	  
GAS-induced NF model, mice lacking hepcidin in keratinocytes failed to restrict 11	  
systemic spread of infection from an initial tissue focus. Unexpectedly, this effect was 12	  
due its ability to promote production of the CXCL1 chemokine by keratinocytes 13	  
resulting in neutrophil recruitment. Unlike CXCL1, hepcidin is resistant to degradation 14	  
by major GAS proteases and could therefore serve as a reservoir to maintain steady 15	  
state levels of CXCL1 in infected tissue. Finally, injection of synthetic hepcidin at the 16	  
site of infection can limit or completely prevent systemic spread of GAS infection 17	  
suggesting that hepcidin agonists could have a therapeutic role in NF.  18	  
 19	  
  20	  
	   3	  
Introduction 1	  
Necrotizing Fasciitis (NF) is an infection characterized by widespread necrosis of the skin, 2	  
subcutaneous tissues and fascia that was first described by Hippocrates in the 5th century (1). 3	  
The standard treatment of NF consists of broad-spectrum antibiotics, extensive surgical 4	  
debridement, and supportive care. However, even with current state-of-the-art treatment, NF 5	  
frequently takes a fulminant course and is still associated with high mortality rates up to 35% 6	  
(1). Group A Streptococcus (GAS) is considered the most common cause of NF associated 7	  
with bacteremia and shock. Upon detection of these Gram-positive pyogenic bacteria, 8	  
neutrophil recruitment is critical to the resolution of infection (2). However, GAS is equipped 9	  
with a magnitude of virulence factors allowing the pathogen to uniquely counteract each anti-10	  
bacterial strategy of neutrophils (3).  11	  
Hepcidin was originally identified as a cationic antimicrobial peptide (AMP) by its close 12	  
structural similarity to the beta defensins but is now also recognized as a key iron regulatory 13	  
hormone (4 ). Hepcidin is mainly produced by the liver in conditions of high iron, infection or 14	  
inflammation. Hepcidin controls plasma iron levels by binding to ferroportin (FPN), the only 15	  
known iron exporter, and inducing its degradation (5). Patients with iron overload are well 16	  
known to be associated with a predisposition to a variety of infections. Hepcidin contributes 17	  
to innate immunity by decreasing plasma iron levels providing an iron-restricted internal 18	  
milieu inhospitable to microbes (6).  19	  
Besides the liver, an increasing number of studies showed that hepcidin is also expressed in 20	  
other tissues (7-10). We previously demonstrated that hepatic hepcidin is sufficient to ensure 21	  
systemic iron homeostasis in physiological conditions (11) suggesting that production of 22	  
hepcidin by other tissues may have local roles. It may have a role at the site of infections 23	  
and/or in poorly perfused tissues, inaccessible by systemic hepcidin from the circulation. The 24	  
putative expression and local role of hepcidin in the skin, major site of AMP production are 25	  
	   4	  
not known. We have employed our recently generated mouse model, in which the hepcidin 1	  
gene can be spatiotemporally inactivated, to explore the putative expression and role of 2	  
hepcidin in the skin in the context of GAS infection. 3	  
  4	  
	   5	  
Results and discussion 1	  
We examined hepcidin expression on skin biopsies derived from patients suffering from GAS 2	  
NF (detailed in Supplementary table 1). Hepcidin staining of human liver tissue sections 3	  
was used as a positive control (Supplementary Figure 1).	  Hepcidin expression was higher 4	  
and more widespread in the skin of NF patients than in the skin of a healthy subject, 5	  
especially in keratinocytes, the predominant cell type in the epidermis (Figure 1A). Hepcidin 6	  
mRNA expression was induced (Figure 1B) in a human 3D organotypic skin model 7	  
(Supplementary Figure 2) as a direct consequence of GAS infection. To investigate the role 8	  
of hepcidin in the development of NF, we used an established model of necrotizing soft tissue 9	  
infection (12, 13) where a strain of GAS, isolated from a patient with NF (14) is introduced 10	  
subcutaneously into a shaved area on the flank of mice. Compared to skin biopsies of healthy 11	  
mice, hepcidin expression was induced in the skin of infected mice (Figure 1C) and clearly 12	  
detected in the keratinocytes as visualized by the Keratin 14 (K14) staining (Figure 1D).  13	  
To probe the functional significance of keratinocyte-derived hepcidin in vivo, we developed a 14	  
mouse model of keratinocyte-specific hepcidin deficiency (Hamp1Δker) by crossing 15	  
Hamp1lox/lox mice with K14cre+ mice (Figure 1E). We observed an efficient truncation of the 16	  
floxed Hamp1 allele in the epidermis of the Hamp1Δker mice but not in the Hamp1lox/lox mice 17	  
or K14-cre+ mice (Supplementary Figure 3). Systemic iron parameters were unchanged 18	  
between Hamp1lox/lox and Hamp1Δker mice (Figure 1F), in agreement with our previous study 19	  
(11) suggesting that hepcidin production by extra-hepatic tissues does not contribute to 20	  
systemic iron homeostasis. Iron levels were also similar in the skin of Hamp1Δker and 21	  
Hamp1lox/lox mice (Figure 1F).  22	  
These mice were infected with GAS in the NF model (14). Keratinocyte hepcidin staining 23	  
was not detectable in the Hamp1Δker mice (Supplementary Figure 4) confirming that the 24	  
	   6	  
stained hepcidin peptide is of skin but not of liver origin. Four days post-infection, Hamp1Δker 1	  
mice had a significantly higher number of bacteria than the Hamp1lox/lox littermates at the 2	  
lesion site (106 vs 105 CFU/mg) but also in the blood (104 vs 9 x 102 CFU/ml) and in the 3	  
spleen (5 x 104 vs 38 CFU/g) (Figure 1G). Hamp1Δker mice also lost more weight than the 4	  
Hamp1lox/lox mice, further underlining the higher morbidity in these mice (Figure 1H). These 5	  
data indicate that keratinocyte production of hepcidin is important in limiting the ability of 6	  
GAS to replicate within the necrotic skin tissues and to disseminate from the initial focus of 7	  
infection into the bloodstream and systemic organs.  8	  
To investigate the mechanisms by which hepcidin protected against the spread of GAS 9	  
infection, we first determined the putative bacteriostatic and bactericidal effects of hepcidin 10	  
against GAS in vitro. While the well-known antimicrobial peptide LL-37 demonstrated 11	  
bacteriostatic activities against GAS (Figures 2A), hepcidin had neither bactericidal (Figures 12	  
2A) nor bacteriostatic activities (Figures 2B). Moreover, primary keratinocytes derived from 13	  
Hamp1lox/lox and Hamp1Δker mice displayed the same bactericidal activity against this 14	  
pathogen (Figure 2C). We therefore ruled out a direct antimicrobial effect of hepcidin on 15	  
these bacteria.  16	  
AMPs have been reported to have pleiotropic effects and influence host’s inflammatory 17	  
responses during infection (15). We therefore asked whether hepcidin could have an 18	  
immunomodulatory role in keratinocytes. For this purpose, we performed a cytoplex on the 19	  
supernatant of murine primary keratinocytes incubated with 0.36 µM and 3.6 µM synthetic 20	  
hepcidin. Interestingly, hepcidin induced a dose-dependent increase of the key neutrophil 21	  
chemokine CXCL1 but not of the other inflammatory cytokines we tested (Figure 2D). The 22	  
capacity of mouse hepcidin to induce CXCL1 in primary keratinocytes was confirmed by 23	  
ELISA (Supplementary Figure 5) as well as the capacity of human hepcidin to induce the 24	  
	   7	  
production of IL-8, the human functional homolog of CXCL1 in the human HaCat 1	  
keratinocyte cell line and in a human 3D organotypic skin model (Figure 2E).  2	  
The cognate receptor of hepcidin is the iron exporter FPN, questioning the role of FPN/iron in 3	  
the induction of CXCL1 by hepcidin. The stimulatory effect of hepcidin on CXCL1 was 4	  
reduced by the addition of a drug preventing the interaction of hepcidin with the iron exporter 5	  
FPN (16) (Figure 2F). These data suggest that hepcidin, in primary keratinocytes, induces 6	  
CXCL1 through a FPN dependent pathway. Binding of hepcidin to FPN is well known to 7	  
induce its internalization and degradation resulting in an increase of intracellular iron (5). In 8	  
corroboration with the action of hepcidin on FPN, incubation of primary keratinocytes with 9	  
iron stimulated CXCL1 production (Figure 2G).  10	  
In agreement with the in vitro results showing that hepcidin stimulates CXCL1 production in 11	  
primary keratinocytes, the in vivo keratinocyte CXCL1 production in response to GAS 12	  
infection was lower in Hamp1Δker mice than in Hamp1lox/lox littermates, as shown by IHC 13	  
(Figure 3A) and ELISA (Figure 3B) on skin biopsies. As a consequence of the lower 14	  
CXCL1 production, less neutrophil recruitment was observed in the skin of Hamp1Δker mice 15	  
compared to that of control littermates, as shown by IHC (Figure 3C) and by cytometry 16	  
analysis (Figure 3D). This defect in the ability of keratinocyte-derived hepcidin to recruit 17	  
neutrophils at the site of infection translated into a decrease in the necrotic skin lesion size of 18	  
the Hamp1Δker mice as compared to controls (Figure 3E). Subcutaneous injection of CXCL1 19	  
into GAS-infected Hamp1Δker mice (Figure 3F) significantly decreased the number of 20	  
bacteria even below to that found in the lesions of Hamp1lox/lox mice (Figure 3G). These 21	  
results strongly suggest that the lack of CXCL1 production in Hamp1Δker mice was 22	  
responsible for their susceptibility to GAS infection. Altogether, these results suggest that 23	  
	   8	  
hepcidin is critical for regulating CXCL1 production in keratinocytes and that it may tune the 1	  
magnitude of the neutrophil recruitment in the immune response. 2	  
We next investigated the possible advantages of indirect production of CXCL1 through 3	  
hepcidin during GAS infection. GAS is equipped with a quantity of neutrophil resistance 4	  
factors allowing the pathogen to uniquely counteract each anti-bacterial strategy of 5	  
neutrophils (3). One of the principal mechanisms of GAS-immune escape is the production of 6	  
surface-associated serine proteases by GAS, such as SpyCEP (also designated ScpC), that 7	  
cleaves human IL-8/mouse CXCL1 to suppress chemokine-mediated neutrophil recruitment 8	  
(17) or SpeB, which allows GAS to translocate across the epithelial barrier by degrading 9	  
several host plasma and matrix proteins (18). To examine whether hepcidin was a target of 10	  
SpyCEP or SpeB, synthetic hepcidin and CXCL1 (as a control) were incubated with purified 11	  
SpyCEP, SpeB or PBS overnight. The digestion products were examined by mass 12	  
spectrometry analyses. As shown by the MALDI spectrum (Figure 4A) CXCL1 was cleaved, 13	  
as expected, into two fragments of 5.9 and 1.3 kDa. In contrast, hepcidin was not cleaved in 14	  
presence of SpyCEP (Figure 4A, bottom panel) or SpeB (Supplementary Figure 6). This 15	  
suggests that hepcidin could serve as a reservoir to maintain a steady-state level of CXCL1 in 16	  
the context of infection. CXCL1 is phylogenetically ancient and is expressed in Dictostelium 17	  
discoideum, while hepcidin-like peptides appeared more recently during evolution, for 18	  
example in teleost fishes (Supplementary Figure 7). Considering the theory that host-19	  
pathogen interactions co-evolve, we could speculate that whereas GAS has already evolved to 20	  
counteract the activity of CXCL1, it has not yet developed a virulence factor able to neutralize 21	  
the activity of hepcidin. Because of hepcidin resistance to bacterial protease activities such as 22	  
SpyCEP or SpeB, and in view of its unanticipated immunomodulatory role, we further asked 23	  
whether local hepcidin injection could have a therapeutic effect on the systemic spread of 24	  
bacteria in a NF model. Twenty-four hours after GAS infection, 1 µg of synthetic hepcidin or 25	  
	   9	  
PBS was subcutaneously injected at the bacterial inoculation site, followed by two injections 1	  
of 500 ng of hepcidin or PBS for 2 consecutive days (Figure 4B). As expected, hepcidin-2	  
treated mice showed an increase in neutrophil recruitment (Figure 4C). In contrast to the 3	  
PBS-treated mice, which exhibited systemic signs of infection including weight loss (Figure 4	  
4D), rough hair coat and hunched posture (data not shown), hepcidin-treated mice did not 5	  
present any signs of systemic disease and accordingly recovered their initial weight. 6	  
Remarkably, whereas all the control mice presented with systemic bacterial dissemination (as 7	  
shown by the number of bacteria in the spleen), 7 out of the 9 hepcidin-treated mice showed 8	  
absolutely no bacterial dissemination (Figure 4E). Hepcidin treatment did not prevent 9	  
bacterial dissemination in CXCL1-/- mice (Supplementary Figure 8), showing that the 10	  
therapeutic effect of hepcidin acted through CXCL1. Hepcidin thus demonstrated a 11	  
therapeutic role in this mouse model of NF. These results suggest that hepcidin represents an 12	  
alternative additional strategy for treating GAS-derived NF, and merits further investigation, 13	  
especially in view of the increasing incidence of invasive GAS disease worldwide (19).  14	  
Altogether, we could speculate that skin hepcidin status (low vs high) may be a marker of 15	  
sepsis development. Future studies should investigate whether skin hepcidin levels inversely 16	  
correlate with the severity of sepsis development in NF patients. 17	  
In addition to its key role as an iron regulatory hormone produced by the liver, we have 18	  
demonstrated here that epidermal hepcidin may also be an essential heretofore unrecognized 19	  
component of the immune response to bacterial infection. Modulation of its expression may 20	  
represent a novel therapeutic approach for necrotizing fasciitis patients. 21	  
  22	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METHODS 1	  
See supplementary information  2	  
Study approval 3	  
For human studies, informed consent to the protocol was obtained for all subjects and was 4	  
approved by the Institutional Review Board and the regional ethics committee Paris IV (IRB 5	  
2016/40NICB), n° IRB 00003835. The collection of personal data was approved by the 6	  
“Commission Nationale de l'Informatique et des Libertés”. 7	  
The animal studies described here were reviewed and approved (Agreement n° 8	  
CEEA34.CP.003.13) by the “Président du Comité d'Ethique pour l'Expérimentation Animale 9	  
Paris Descartes” and are in accordance with the principles and guidelines established by the 10	  
European Convention for the Protection of Laboratory Animals (Council of Europe, ETS 123, 11	  
1991). 12	  
  13	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FIGURE LEGENDS 1	  
 2	  
Figure 1. Keratinocyte hepcidin prevents bacterial systemic spread 3	  
Immunohistochemistry (IHC) with or without primary antibody detecting (A) hepcidin (in 4	  
brown) on sections of cutaneous human biopsies of GAS NF patients and healthy control 5	  
using PerkinElmer's LaminaTM multilabel slide scanner Panoramic Viewer software. (B) Q-6	  
PCR for hepcidin from GAS-infected human 3D organotypic skin equivalent model. N=4 per 7	  
group. (C) Q-PCR for hepcidin in murine GAS-infected skin. N ≥ 3 per group. (D) Hepcidin 8	  
(in blue) and K14 (in brown) IHC on cutaneous biopsies of WT mice challenged or not with 9	  
GAS. Bars represent 100 µm. (5/0.4, Leica DMI3000B microscope, Leica DFC310FX camera 10	  
[Leica LAS Core software]). (E) Generation of Hamp1Δker mice. (F) Plasma iron, ferritin, 11	  
transferrin and skin iron levels in Hamp1lox/lox and Hamp1Δker mice. N ≥ 4 per group. (G) 12	  
Bacterial count in skin, blood and spleen of Hamp1lox/lox and Hamp1Δker  mice four days after 13	  
injection with GAS. N ≥ 10 per group. (H) Weight variation of Hamp1lox/lox and Hamp1Δker 14	  
mice during infection. N=10 per group. Statistical analysis was performed using a Mann 15	  
Whitney test (B, C, F, G) or a two-way analysis of variance (ANOVA) followed by a Tukey 16	  
test for weight kinetics (H).  17	  
 18	  
Figure 2. Hepcidin promotes CXCL1 production by keratinocytes 19	  
(A) GAS killing kinetics with 32 µM of LL-37 and hepcidin. N=3 per group. Representative 20	  
of 2 independent experiments. (B) GAS growth curve in the presence of pennicilin G, LL-37, 21	  
hepcidin or PBS. N=3 per group. Representative of 2 independent experiments. (C) Bacterial 22	  
recovering at 1h and 3h following incubation of log-phase GAS with murine primary 23	  
keratinocytes (KC) from Hamp1lox/lox and Hamp1Δker mice. Data are representative of two 24	  
	   16	  
independent experiments performed in triplicate. (D) Cytokines measured with the V-PLEX 1	  
Proinflammatory Panel1 kit in the culture supernatant of murine primary keratinocytes 2	  
stimulated for 1 or 3 h with hepcidin or PBS. N=3 per group. Representative of 3 independent 3	  
experiments. (E) IL-8 ELISA on the culture supernatant of HaCat or a human 3D skin 4	  
equivalent model stimulated with 3.6 µM hepcidin. N≥3 per group. (F) CXCL1 levels 5	  
measured by ELISA in the culture supernatant of murine primary keratinocytes stimulated for 6	  
3 h with 3.6 µM hepcidin in presence of PBS or 100 µM FPN inhibitor (2D-014). N ≥ 3 per 7	  
group. Representative of 3 independent experiments. (G) CXCL1 levels measured by ELISA 8	  
on the culture supernatant of murine primary keratinocytes stimulated for 3 h with 500 µM 9	  
Ferric Ammonium Citrate (FAC). N=3 per group. Representative of 3 independent 10	  
experiments. Statistical analysis was performed using a two-way ANOVA followed by a 11	  
Tukey test (A,B,D), unpaired Student’s t-test (E, G) or a one-way ANOVA followed by a 12	  
Tukey test (C,F). 13	  
 14	  
Figure 3. Hepcidin is required for CXCL1 production and neutrophil recruitment 15	  
(A) Anti-CXCL1 or (C) anti polymorphonuclear leucocytes (PMN) immunostainings on skin 16	  
of Hamp1lox/lox and Hamp1Δker mice challenged with GAS. PerkinElmer's LaminaTM 17	  
multilabel slide scanner Panoramic Viewer software. (B) CXCL1 ELISA on lysates from 18	  
GAS-infected skin biopsies of Hamp1lox/lox (n=5) and Hamp1Δker mice (n=6). (D) Neutrophil 19	  
count from GAS-infected skin biopsies of Hamp1lox/lox (n=5) and Hamp1Δker mice (n=4). (E) 20	  
Area of necrotic ulcers in skin of Hamp1lox/lox and Hamp1Δker mice during GAS infection. 21	  
N=7 per group. (F) Scheme of the study protocol. (G) Bacterial count in the skin of 22	  
Hamp1lox/lox and Hamp1Δker mice injected daily with CXCL1 or PBS. N≥4 per group. 23	  
	   17	  
Statistical analysis was performed using a Student’s t-test (B, D), a two-way ANOVA 1	  
followed by a Tukey test (E) or a one-way ANOVA followed by a Tukey test (G). 2	  
 3	  
Figure 4. Hepcidin is resistant to SpyCEP cleavage and has a therapeutic role in NF  4	  
 (A) Mass spectroscopy analysis of CXCL1 or hepcidin incubated overnight with SpyCEP or 5	  
PBS. Electrospray ionization generated a series of multiply charged ions (indicated as m/z; 6	  
mass-to-charge ratio) from which the average molecular mass (m) of each was deduced. The 7	  
blue arrows indicate uncleaved peptide peaks at 7.8 kDa (CXCL1) and 2.7 kDa (hepcidin). 8	  
Red arrows show the cleavage products of CXCL1 with a small (1.3 kDa) and a big (5.9 kDa) 9	  
fragment. (B) Therapeutic protocol. (C) Neutrophil count (three measurements per individual 10	  
mouse were averaged). N=6 per group (D) Weight variation and (E) bacterial count in spleen 11	  
of WT infected mice treated with PBS or hepcidin (n=9, red square) or PBS (n=9, black 12	  
square) during 4 days. Statistical analysis was performed using a Student’s t-test (C), a two-13	  
way ANOVA followed by a Tukey test (D) or a Mann Whitney test (E). 14	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Figure 1. Keratinocyte hepcidin prevents bacterial systemic spread 
Immunohistochemistry (IHC) with or without primary antibody detecting (A) hepcidin (in brown) on sections of cutaneous human biopsies 
of GAS NF patients and healthy control using PerkinElmer's LaminaTM multilabel slide scanner Panoramic Viewer software. (B) Q-PCR 
for hepcidin from GAS-infected human 3D organotypic skin equivalent model. N=4 per group. (C) Q-PCR for hepcidin in murine GAS-
infected skin. N≥3 per group. (D) Hepcidin (in blue) and K14 (in brown) IHC on cutaneous biopsies of WT mice challenged or not with 
GAS. Bars represent 100 µm. (5/0.4, Leica DMI3000B microscope, Leica DFC310FX camera [Leica LAS Core software]). (E) Generation 
of Hamp1Δkermice. (F) Plasma iron, ferritin, transferrin and skin iron levels in Hamp1lox/lox and Hamp1Δker mice. N ≥ 4 per group. (G) 
Bacterial count in skin, blood and spleen of Hamp1lox/lox and Hamp1Δkermice four days after injection with GAS. N ≥ 10 per group. (H) 
Weight variation of Hamp1lox/lox and Hamp1Δker  mice during infection. N=10 per group. Statistical analysis was performed using a Mann 
Whitney test (B, C, F, G) or a two-way analysis of variance (ANOVA) followed by a Tukey test for weight kinetics (H). 
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FIGURE 2 
Figure 2. Hepcidin promotes CXCL1 production by keratinocytes 
(A) GAS killing kinetics with 32 µM of LL-37 and hepcidin. N=3 per group. Representative of 2 independent experiments. (B) GAS 
growth curve in the presence of pennicilin G, LL-37, hepcidin or PBS. N=3 per group. Representative of 2 independent experiments. (C) 
Bacterial recovering at 1h and 3h following incubation of log-phase GAS with murine primary keratinocytes (KC) from Hamp1lox/lox and 
Hamp1Δker mice. Data are representative of two independent experiments performed in triplicate. (D) Cytokines measured with the V-
PLEX Proinflammatory Panel1 kit in the culture supernatant of murine primary keratinocytes stimulated for 1 or 3 h with hepcidin or 
PBS. N=3 per group. Representative of 3 independent experiments. (E) IL-8 ELISA on the culture supernatant of HaCat or a human 3D 
skin equivalent model stimulated with 3.6 µM hepcidin. N≥3 per group. (F) CXCL1 levels measured by ELISA in the culture supernatant 
of murine primary keratinocytes stimulated for 3 h with 3.6 µM hepcidin in presence of PBS or 100 µM FPN inhibitor (2D-014). N≥ 3 per 
group. Representative of 3 independent experiments. (G) CXCL1 levels measured by ELISA on the culture supernatant of murine 
primary keratinocytes stimulated for 3 h with 500 µM Ferric Ammonium Citrate (FAC). N≥3 per group. Representative of 3 independent 
experiments. Statistical analysis was performed using a two-way ANOVA followed by a Tukey test (A,B,D), unpaired Student’s t-test (E, 
G) or a one-way ANOVA followed by a Tukey test (C,F). 
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+ CXCL1 Figure 3. Hepcidin is required for CXCL1 production and neutrophil recruitment 
(A) Anti-CXCL1 or (C) anti polymorphonuclear leucocytes (PMN) immunostainings on skin of Hamp1lox/lox and Hamp1Δker mice 
challenged with GAS. PerkinElmer's LaminaTM multilabel slide scanner Panoramic Viewer software. (B) CXCL1 ELISA on lysates from 
GAS-infected skin biopsies of Hamp1lox/lox (n=5) and Hamp1Δker mice (n=6). (D) Neutrophil count from GAS-infected skin biopsies of 
Hamp1lox/lox (n=5) and Hamp1Δker mice (n=4). (E) Area of necrotic ulcers in skin of Hamp1lox/lox and Hamp1Δker mice during GAS 
infection. N=7 per group. (F) Scheme of the study protocol. (G) Bacterial count in the skin of Hamp1lox/lox and Hamp1Δker mice injected 
daily with CXCL1 or PBS. N≥4 per group. Statistical analysis was performed using a Student’s t-test (B, D), a two-way ANOVA followed 
by a Tukey test (E) or a one-way ANOVA followed by a Tukey test (G). 
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FIGURE 4 
Figure 4. Hepcidin is resistant to SpyCEP cleavage and has a therapeutic role in NF  
(A) Mass spectroscopy analysis of CXCL1 or hepcidin incubated overnight with SpyCEP or PBS. Electrospray ionization generated a 
series of multiply charged ions (indicated as m/z; mass-to-charge ratio) from which the average molecular mass (m) of each was 
deduced. The blue arrows indicate uncleaved peptide peaks at 7.8 kDa (CXCL1) and 2.7 kDa (hepcidin). Red arrows show the cleavage 
products of CXCL1 with a small (1.3 kDa) and a big (5.9 kDa) fragment. (B) Therapeutic protocol. (C) Neutrophil count (three 
measurements per individual mouse were averaged). N=6 per group (D) Weight variation and (E) bacterial count in spleen of WT 
infected mice treated with PBS or hepcidin (n=9, red square) or PBS (n=9, black square) during 4 days. Statistical analysis was 
performed using a Student’s t-test (C), a two-way ANOVA followed by a Tukey test (D) or  a Mann Whitney test (E). 
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